Cancer Stem Cell News Volume 12.08 | Mar 1 2023


    2023-03-01 | CSCN 12.08

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 12.08 – 1 March, 2023

    PMN-MDSCs Modulated by CCL20 from Cancer Cells Promoted Breast Cancer Cell Stemness through CXCL2-CXCR2 Pathway

    Investigators observed that polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) were remarkably enriched in the tumor microenvironment of CCL20-overexpressing cancer cell orthotopic allograft tumors.
    [Signal Transduction and Targeted Therapy]

    Full Article
    PUBLICATIONSRanked by the impact factor of the journal

    mcPgk1-Dependent Mitochondrial Import of PGK1 Promotes Metabolic Reprogramming and Self-Renewal of Liver TICs

    Researchers identified a mitochondria-encoded circular RNA termed mcPGK1, mitochondrial circRNA for translocating phosphoglycerate kinase 1, which was highly expressed in liver tumor-initiating cells.
    [Nature Communications]

    Full Article

    Photothermal Attenuation of Cancer Cell Stemness, Chemoresistance, and Migration Using CD44-Targeted MoS2 Nanosheets

    Investigators introduced a nanomaterial-based approach to photothermally induce the differentiation of CSCs, termed “photothermal differentiation”, leading to the attenuation of cancer cell stemness, chemoresistance, and metastasis.
    [Nano Letters]

    AbstractGraphical Abstract

    An Iron Oxyhydroxide-Based Nanosystem Sensitizes Ferroptosis by a “Three-Pronged” Strategy in Breast Cancer Stem Cells

    Scientists designed a hyaluronic acid-coated siProminin2-loaded FeOOH nano-drug to accelerate ferroptosis of breast CSCs by simultaneously increasing iron ion content, inhibiting iron efflux, and scavenging glutathione.
    [Acta Biomaterialia]

    AbstractGraphical Abstract

    Plexin-B3 Expression Stimulates MET Signaling, Breast Cancer Stem Cell Specification, and Lung Metastasis

    Researchers reported that Plexin B3 (PLXNB3) expression was increased in response to hypoxia and that PLXNB3 was a direct target gene of hypoxia-inducible factor 1 in human breast cancer cells.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Lipogenesis Promotes Mitochondrial Fusion and Maintains Cancer Stemness in Human NSCLC

    The authors pinpointed OPA1high with mitochondrial fusion as a metabolic feature of human lung CSCs, licensing their stem-like properties.
    [JCI Insight]


    SCF-FBXL8 Contributes to Liver Metastasis and Stem-Cell-Like Features in Colorectal Cancer Cells by Mediating Ubiquitination and Degradation of TP53

    The up-regulation of FBXL8 promoted the proliferation, invasion, and migration of colorectal cancer tumor cells and maintained the stem-cell characteristics of colorectal tumor cells.
    [Clinical and Translational Medicine]

    Full Article

    Exploiting the Receptor-Binding Domains of RSPO1 to Target LGR5-Expressing Stem Cells in Ovarian Cancer

    In order to target stem cells in ovarian cancer, scientists used the sortase reaction to site-specifically conjugate the potent cytotoxin monomethyl auristatin E and their co-receptors ZNRF3 and RNF43 via a protease-cleavable linker.
    [Journal of Pharmacology and Experimental Therapeutics]

    AbstractFull Article

    Erythrose Inhibits the Progression to Invasiveness and Reverts Drug Resistance of Cancer Stem Cells of Glioblastoma

    Investigators evaluated the effect of the tetrose saccharide, erythrose, a neuroleukin inhibitor of invasiveness and drug sensitization in glioblastoma stem cells.
    [Medical Oncology]

    Survey results on the needs and challenges in the human pluripotent stem cell field

    N6-Methyladenosine (m6A) as a Regulator of Carcinogenesis and Drug Resistance by Targeting Epithelial-Mesenchymal Transition and Cancer Stem Cell

    The authors review up-to-date knowledge of the relationship between m6A modulation and drug resistance and discuss the regulation of m6A modulation in epithelial-mesenchymal transition and CSCs.

    Full Article

    Tachyon Receives Funding from CIRM for a Phase I Clinical Study of TACH101, a First-in-Class KDM4 Inhibitor, in Patients with Advanced Solid Tumors

    Tachyon Therapeutics, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $7.1 million grant to support a Phase I clinical study of TACH101 in patients with advanced solid tumors.
    [Tachyon Therapeutics, Inc.]

    Press Release

    Cell Culture Engineering XVIII

    April 23 – 28, 2023
    Cancun, Mexico

    > See All Events


    Postdoctoral Fellow – Cancer Stem Cells in Metastasis

    Albert Einstein College of Medicine – New York, New York, United States

    Computational Biologist – Cancer and Glioma Stem Cell Biology

    Weill Cornell College of Medicine – New York, New York, United States

    Postdoctoral Researcher – Type III Collagen

    Penn Medicine – Philadelphia, Pennsylvania, United States

    Postdoctoral Research Fellow – Cancer Biology

    The Henry Ford Health System – Detroit, Michigan, United States

    Research Fellow – Molecular and Cellular Biology

    The University of Melbourne – Melbourne, Australia

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter